Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
<p>Supplemental Figure S6: In vivo efficacy of a range of doses of CLDN6-23-ADC in M202 xenograft models. ADC dosing is IV QW as indicated by the arrows</p>
Gorde:
| Egile nagusia: | |
|---|---|
| Beste egile batzuk: | , , , , , , , , , , , , , , , , , , |
| Argitaratua: |
2025
|
| Gaiak: | |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
| _version_ | 1849927633728438272 |
|---|---|
| author | Martina S.J. McDermott (15206951) |
| author2 | Neil A. O'Brien (15206954) Benjamin Hoffstrom (15206957) KeWei Gong (15206960) Ming Lu (15206963) Jun Zhang (15206966) Tong Luo (15206969) Min Liang (15206972) Weiping Jia (15206975) Jenny J. Hong (15206978) Kevin Chau (15206981) Simon Davenport (15206984) Bin Xie (15206987) Michael F. Press (15206990) Richard Panayiotou (15206993) Abram Handly-Santana (15206996) Joan S. Brugge (9710515) Leonard Presta (15206999) John Glaspy (15207002) Dennis J. Slamon (15047067) |
| author2_role | author author author author author author author author author author author author author author author author author author author |
| author_facet | Martina S.J. McDermott (15206951) Neil A. O'Brien (15206954) Benjamin Hoffstrom (15206957) KeWei Gong (15206960) Ming Lu (15206963) Jun Zhang (15206966) Tong Luo (15206969) Min Liang (15206972) Weiping Jia (15206975) Jenny J. Hong (15206978) Kevin Chau (15206981) Simon Davenport (15206984) Bin Xie (15206987) Michael F. Press (15206990) Richard Panayiotou (15206993) Abram Handly-Santana (15206996) Joan S. Brugge (9710515) Leonard Presta (15206999) John Glaspy (15207002) Dennis J. Slamon (15047067) |
| author_role | author |
| dc.creator.none.fl_str_mv | Martina S.J. McDermott (15206951) Neil A. O'Brien (15206954) Benjamin Hoffstrom (15206957) KeWei Gong (15206960) Ming Lu (15206963) Jun Zhang (15206966) Tong Luo (15206969) Min Liang (15206972) Weiping Jia (15206975) Jenny J. Hong (15206978) Kevin Chau (15206981) Simon Davenport (15206984) Bin Xie (15206987) Michael F. Press (15206990) Richard Panayiotou (15206993) Abram Handly-Santana (15206996) Joan S. Brugge (9710515) Leonard Presta (15206999) John Glaspy (15207002) Dennis J. Slamon (15047067) |
| dc.date.none.fl_str_mv | 2025-11-25T13:00:32Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30706649 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Figure_S6_from_Preclinical_Efficacy_of_the_Antibody_Drug_Conjugate_CLDN6_23-ADC_for_the_Treatment_of_CLDN6-Positive_Solid_Tumors/30706649 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Therapeutic Research and Development Biological Agents & Therapies Antibody-drug conjugates Gynecological Cancers Endometrial cancer Ovarian cancer Translational Research |
| dc.title.none.fl_str_mv | Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Supplemental Figure S6: In vivo efficacy of a range of doses of CLDN6-23-ADC in M202 xenograft models. ADC dosing is IV QW as indicated by the arrows</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_a653a24b48a08c9e4d5aac112d6afffc |
| identifier_str_mv | 10.1158/1078-0432.30706649 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30706649 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid TumorsMartina S.J. McDermott (15206951)Neil A. O'Brien (15206954)Benjamin Hoffstrom (15206957)KeWei Gong (15206960)Ming Lu (15206963)Jun Zhang (15206966)Tong Luo (15206969)Min Liang (15206972)Weiping Jia (15206975)Jenny J. Hong (15206978)Kevin Chau (15206981)Simon Davenport (15206984)Bin Xie (15206987)Michael F. Press (15206990)Richard Panayiotou (15206993)Abram Handly-Santana (15206996)Joan S. Brugge (9710515)Leonard Presta (15206999)John Glaspy (15207002)Dennis J. Slamon (15047067)CancerTherapeutic Research and DevelopmentBiological Agents & TherapiesAntibody-drug conjugatesGynecological CancersEndometrial cancerOvarian cancerTranslational Research<p>Supplemental Figure S6: In vivo efficacy of a range of doses of CLDN6-23-ADC in M202 xenograft models. ADC dosing is IV QW as indicated by the arrows</p>2025-11-25T13:00:32ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30706649https://figshare.com/articles/figure/Figure_S6_from_Preclinical_Efficacy_of_the_Antibody_Drug_Conjugate_CLDN6_23-ADC_for_the_Treatment_of_CLDN6-Positive_Solid_Tumors/30706649CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307066492025-11-25T13:00:32Z |
| spellingShingle | Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors Martina S.J. McDermott (15206951) Cancer Therapeutic Research and Development Biological Agents & Therapies Antibody-drug conjugates Gynecological Cancers Endometrial cancer Ovarian cancer Translational Research |
| status_str | publishedVersion |
| title | Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors |
| title_full | Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors |
| title_fullStr | Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors |
| title_full_unstemmed | Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors |
| title_short | Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors |
| title_sort | Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors |
| topic | Cancer Therapeutic Research and Development Biological Agents & Therapies Antibody-drug conjugates Gynecological Cancers Endometrial cancer Ovarian cancer Translational Research |